Trial Profile

Multicenter, Open-label, Randomized, Controlled, Parallel Arms Clinical Study on Performance of SGM-101, a Fluorochrome-labeled Anti-CEA Monoclonal Antibody, for Delineation of Primary/Recurrent Tumor and Metastases in Patients Undergoing Surgery for Colorectal Cancer

Status: Recruiting

Phase of Trial: Phase III

Latest Information Update: 26 Apr 2024

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs SGM 101 (Primary)
Indications Cancer metastases; Colon cancer; Colorectal cancer; Rectal cancer
Focus Diagnostic use; Registrational
Sponsors SurgiMAb

04 May 2022 Planned End Date changed from 1 Dec 2021 to 1 Dec 2023.
04 May 2022 Planned primary completion date changed from 1 Nov 2021 to 1 Nov 2023.
20 Oct 2020 Planned End Date changed from 1 Dec 2020 to 1 Dec 2021.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com